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ier Paolo Di Fiore likes to describe 
his scientifi  c successes as bits of 
happenstance—that as he and his 
colleagues pursued the next logical step 
in a sequence of experimental inquiry, 
luck often handed them something even 
more interesting to run with. Others 
would surely describe it as the payoff for 
perseverance that has led Di Fiore from 
studying cancer to endocytosis and back 
to cancer again. Along the way, his group 
was largely responsible for a mini-explo-
sion of new ideas about how endocytosis 
functions well beyond its traditional role 
of intracellular traffi  cking to act as an 
all-around signaling platform that con-
trols key cellular processes such as the 
cell cycle.
As a “restless” medical student in 
Italy, Di Fiore began studying retrovi-
ruses, at the time the preferred model for 
cancer research. In 1984, he arrived in the 
US as a postdoc to study growth factor 
receptor tyrosine kinases, such as EGFR, 
at the National Cancer Institute (NCI) in 
Bethesda, Maryland, where 
he would eventually become 
a section chief.
At the start of the 
1990s his laboratory identi-
fi  ed EPS15 as a substrate for 
the EGFR’s tyrosine kinase 
activity (1). Further prob-
ing in Di Fiore’s and other 
laboratories revealed that 
EPS15 plays a vital role 
in endocytosis, exhibiting 
a new form of signaling 
involving monoubiquitina-
tion (2). Recently, his group has shown 
that EGFR signaling gets prolonged or 
shut down depending on which endocytic 
pathway engulfs the receptor (3).
In addition, Di Fiore has become an 
adept wrestler of the new and mysterious 
“beasts” that come his way from fi  sh-
ing among cell signaling pathways. One 
such pursuit led to startling connections 
between the cell fate determinant Numb, 
endocytosis, breast cancer, and the tumor 
suppressor p53 (4, 5).
Di Fiore returned to his homeland 
14 years ago to direct the Experimental 
Oncology department of the European 
Institute of Oncology in Milan. In 2001, 
he was asked to head up IFOM, the FIRC 
Institute of Molecular Oncology. Also 
a professor at the University of Milan, 
he stepped down from running IFOM in 
January 2009 to resume being a “full-
time scientist.” He shares his thoughts on 
research funding in Europe, how the en-
docytic system is like a Roman road, and 
why he misses American food.
CHANGING THE TEXTBOOKS
The old view of endocytosis was that it 
attenuated signaling by engulﬁ  ng cell 
surface receptors and dooming them to 
degradation. How did that view change 
during your career?
People were wondering whether endo-
cytosis had a role in signaling because 
the receptors were still active in the en-
docytic compartment. The 
real question was, “What 
is the productive part of 
signaling? Does it only 
happen at the plasma 
membrane or is what hap-
pens in the endocytic route 
also important?”
Everything changed 
when Sandy Schmid’s 
laboratory published their 
1996 Science paper on the 
dominant-negative mutant 
of dynamin. She showed 
that when endocytosis was inhibited, 
certain signaling pathways were se-
verely impaired. That’s the moment 
that even old-fashioned signalers like 
me started thinking that maybe endo-
cytosis played a major role in signal-
ing. Today, we think that endocytosis 
is the framework on which signaling is 
written—basically they are two sides of 
the same coin.
What makes endosomes good platforms 
for signaling?
When we thought that all signaling was 
from the plasma membrane, the simple 
fact that another compartment could work 
for signaling was pretty novel. But endo-
somes make very unique signaling stations 
because they have some peculiar charac-
teristics. Endosomes are small and so they 
concentrate proteins on the membrane. 
They are rich in certain molecules not on 
the plasma membrane, such as PI3P, a 
signaling lipid, and p18, an anchoring 
protein for ERK signaling. Endosomes 
are acidic, which is key for a number of 
signal transduction pathways.
I could go on and on, but the concept 
today is that it’s not just another station for 
signaling, but it is a privileged platform 
where a number of things happen that 
could not occur on the plasma membrane.
THUMBING A RIDE
You’ve likened endocytosis routes to the 
Roman road system, which was developed 
to move armies, but then quickly used for 
communication and commerce as well. 
How did endocytosis get repurposed?
Well, it’s an infrastructure. And once the 
infrastructure is there, the cell is normally 
“smart” enough to fi  gure out ways to use 
it for different things. The initial selective 
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pressure to develop an endocytic system 
was most likely to gulp down other cells and 
get easy access to nutrients—at least that’s 
what a lot of evolutionary biologists think.
You have to endocytose membrane 
and then you have to somehow put mem-
brane back on the plasma membrane, and 
so you start developing an endocytic and 
exocytic cycle. At a certain point—regard-
less of the evolutionary reason—you fi  nd 
yourself with a very powerful network that 
can move things around the cell.
And you’ve extended the road analogy 
to include hijackers and hitchhikers?
Yes, so now the question is: Are other 
functions going to parasitize this infra-
structure? Probably, yes—we know al-
ready that there are pathogens that parasit-
ize the endocytic system. Of course, some-
body from the outside doesn’t need to be 
very careful—he can just hijack the entire 
system and use it for his own purpose.
But, if the cell wants to use the sys-
tem, it has to do so without destroying it. 
The fi  rst step might have been molecules 
that hitched a ride on the system—to 
move faster, or reach other 
destinations, or to be seg-
regated. Those hitchhikers, 
as I call them, might have 
“learned” to do something 
for endocytosis as well. 
They might have learned 
how to pay their fare.
Of course, this idea 
might turn out to be wrong. 
We pay a lot of attention to 
how things are, but I do be-
lieve that we also have to pay 
attention to how things came 
into being. It’s important 
because we can learn from 
that. But, I wouldn’t want my scientifi  c 
career to be remembered for a hypothesis… 
unless it turns out to be a smashing success!
Your group showed that Numb—a 
protein normally associated with cell 
fate determination—is an important 
player in breast cancer. How did you 
make this connection?
We screened for proteins that interacted 
with EPS15, and one of the proteins that 
came out was Numb. 
What is Numb? We’d never 
seen it before. This is what 
happens when you do 
signaling—you’re always 
fi   shing out a different 
beast that you have never 
seen or worked with. It’s 
very interesting but also 
frustrating because you’re 
working in an area in 
which a lot of people are 
better than you are.
But, on the other 
hand, you bring a novel 
outlook to the area. We 
did the obvious experi-
ments to show that Numb 
was a bona fi  de endocytic protein. Then 
we got lucky with the tumor connection. 
One of the fi  rst things I did when I came 
back to Italy was to set up a molecular 
pathology unit that would routinely 
screen human tumors for all the proteins 
we were fi  shing out from our work. And 
it turned out that Numb was lost in 50% 
of breast cancers.
FOR THE LOVE OF 
MONEY AND FOOD
What is the current 
funding atmosphere like 
in Europe for scientiﬁ  c 
research?
The economic downturn is 
hitting everybody of course, 
but there are two levels to 
consider in Europe: the na-
tional level and the Europe-
an Commission. At the EC 
level, the situation has actu-
ally improved. Two years 
ago, they introduced indi-
vidual European Research Council (ERC) 
grants, which are very similar to the US 
RO1 grants. These are very good grants.
But at the national level, at least in 
Italy, the matter is really problematic. The 
money for Italian research has never been 
much and has become less and less with 
the economic crisis. I’m lucky because our 
institution is well funded through private 
foundations and charities, but you cannot 
run the research of an entire nation through 
those. But, I’m not much for complaining, 
and I think in diffi  cult times, you roll up 
your sleeves and your character comes out.
You were at the NCI for 12 years: what 
do you miss about the States?
When asked this question, I give an answer 
and everybody laughs: I miss the food. And 
you will say, “Food is fantastic in Italy!” 
Yes, but it’s Italian. In the States you are 
exposed to so many different cuisines.
There’s a deeper meaning to what 
I’m saying. What I miss about the States 
is the multiculturality, and the fact that 
there is a little piece of something for 
everybody in America. America belongs 
to everybody; Italy belongs to the Italians. 
I never felt like a stranger in the States, 
from the moment I fi  rst set foot there.
What type of cuisine did you enjoy most?
I love everything. I got introduced to sushi 
in the States, and I can easily run up a $200 
bill at a sushi restaurant with my wife. In 
the Washington area there were all kinds of 
fantastic food: Indonesian, Chinese, Indi-
an, Thai—you’re exposed to everything. 
Ethiopian food—eating with your hands, 
now that’s a very rewarding experience.
I knew we were going to end up 
talking about food!
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Di Fiore and family, visiting the Chateau d’Amboise in France, 
the burial place of Leonardo da Vinci.
 “I wouldn’t 
want my 
scientific 
career to be 
remembered for 
a hypothesis… 
unless it turns 
out to be a 
smashing 
success!”